BeStock  
Stocks › Biotechnology › SRPT

Sarepta Therapeutics SRPT

US equityMarket cap rank #2908Biotechnology
$13.33 −$0.84 (-5.93%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $13.60 +2.03%
Open$13.92
Prev close$14.17
Day range$13.25 – $14.47
Volume2.25M
Market cap$1.43B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±8.4%last 16 reports
Closed higher7 of 1644% of the time
Best reaction+19.2%
Worst reaction-33.7%

Stock move on the day after each report

-7.0%2023/Q4-0.2%2024/Q1-2.6%2024/Q2-5.9%2024/Q3-3.6%2024/Q4-21.5%2025/Q1+10.5%2025/Q2-33.7%2025/Q3-8.0%2025/Q4-9.7%2026/Q1+5.3%2026/Q2+1.4%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q35 Nov 2026After Market±21.0%+1.42%Within range
2026/Q25 Aug 2026After Market±8.0%+5.34%Within range
2026/Q16 May 2026After Market±9.4%-9.68%Bigger than priced
2025/Q425 Feb 2026After Market±9.8%-8.01%Within range
2025/Q33 Nov 2025After Market±19.5%-33.74%Bigger than priced
2025/Q26 Aug 2025After Market±12.4%+10.46%Within range
2025/Q16 May 2025After Market±16.9%-21.45%Bigger than priced
2024/Q426 Feb 2025After Market±7.9%-3.56%Within range
2024/Q36 Nov 2024After Market±9.4%-5.90%Within range
2024/Q27 Aug 2024After Market±10.6%-2.61%Within range
2024/Q11 May 2024After Market±7.2%-0.21%Within range
2023/Q428 Feb 2024After Market±7.9%-6.98%Within range
2023/Q31 Nov 2023After Market±8.8%+1.62%Within range
2023/Q22 Aug 2023After Market±6.5%+2.05%Within range
2023/Q12 May 2023After Market±6.8%+1.41%Within range
2022/Q428 Feb 2023After Market±7.2%+19.24%Bigger than priced

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Phosphorodiamidate morpholino oligomer (PMO) product revenues, net$240.31M 63.0%
  • ELEVIDYS product revenues, net$83.45M 21.9%
  • Collaboration and other$57.59M 15.1%

Latest reported quarter: Q3, ended Sep 2026

Revenue$381.35M-4.5% YoY
Operating profit-$9.04M+85.6% YoY
Net profit-$28.46M+43.7% YoY
Diluted EPS-$0.27+46.0% YoY
Free cash flow$53.83M+226.4% YoY
Operating cash flow$59.97M

Revenue, last 8 quarters

$658.4MDec '24$744.9MMar '25$611.1MJun '25$399.4MSep '25$442.9MDec '25$730.8MMar '26$401.3MJun '26$381.4MSep '26

Net profit, last 8 quarters

$159.0MDec '24$-447.5MMar '25$196.9MJun '25$-50.6MSep '25$-412.2MDec '25$331.0MMar '26$-4.9MJun '26$-28.5MSep '26

Profitability & balance sheet

Gross margin56.8%
Operating margin-0.4%
Net margin-5.9%
Return on equity-8.0%
Return on assets-3.4%
Return on invested capital-3.1%
Current ratio3.46
Liabilities / assets51.7%
Cash & investments$878.78M
Total debt$1.05B
Net cash (debt)-$174.25M
Free cash flow / sales8.8%

Discussion

No comments yet — be the first to weigh in on SRPT.

Sign in to join the discussion.

Scroll to Top